Gravity Analytica

Aldeyra Therapeutics Selected to Present at the Disruptive Innovations Symposium during the OSN New York Retina 2024 Meeting

ALDX 10.31.2024

SERA-AI Powered Highlights

Drug:ADX-2191 ADX-2191

Diseases:retinitis pigmentosa

Date of Upcoming Event:2024-11-08

Name of Upcoming Event:Disruptive Innovations Symposium

Full Press Release SEC Filings Our ALDX Tweets

About Gravity Analytica

Recent Filings

PDF Version

LEXINGTON, Mass.--(BUSINESS WIRE)--Oct. 31, 2024--Aldeyra Therapeutics, Inc.(Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced thatTomasz Stryjewski, M.D., Chief Medical Advisor - Retina, will present at the Disruptive Innovations Symposium during theOcular Surgery News(OSN) New York Retina 2024 Meeting, which takes place inNew York, New YorkNovember 8-10, 2024.

Dr. Stryjewskiwill provide an overview of the Phase 2/3 clinical development of ADX-2191 in retinitis pigmentosa. The session will run from 3:30 –5:30 p.m. ETonFriday, November 8, 2024.

About Aldeyra

Aldeyra Therapeuticsis a biotechnology company devoted to discovering innovative therapies designed to treat immune-mediated and metabolic diseases. Our approach is to develop pharmaceuticals that modulate protein systems, instead of directly inhibiting or activating single protein targets, with the goal of optimizing multiple pathways at once while minimizing toxicity. Our product candidates include RASP (reactive aldehyde species) modulators ADX-629, ADX-248, ADX-743, ADX-631, and chemically related molecules for the potential treatment of systemic and retinal immune-mediated and metabolic diseases. Our late-stage product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal methotrexate for the potential treatment of retinitis pigmentosa.

View source version onbusinesswire.com:https://www.businesswire.com/news/home/20241031692801/en/

Investor & Media Contact:Laura NicholsTel: (781) 257-3060investorrelations@aldeyra.com

Source:Aldeyra Therapeutics, Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com